Imago BioSciences Revenue and Competitors

Claim your profile

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Imago BioSciences's estimated annual revenue is currently $5.3M per year.(i)
  • Imago BioSciences's estimated revenue per employee is $135,128
  • Imago BioSciences's current valuation is $619.6M. (January 2022)

Employee Data

  • Imago BioSciences has 39 Employees.(i)
  • Imago BioSciences grew their employee count by 44% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

Our scientific efforts are aimed at developing drugs that improve the management of proliferative diseases of the bone marrow. Our clinical focus is on acute myeloid leukemia, myelodysplastic syndrome, polycythemia vera, myelofibrosis and essential thrombocythemia. These diseases share several features. They are diseases caused by acquired mutations in blood stem cells. To varying degrees, these mutations drive excessive growth of bone marrow cells, as well as alter their function. For example, myelofibrosis can be viewed as a chronic inflammatory disorder in which inflammatory cytokines and growth factors cause bone marrow cells to alter the architecture of and ultimately destroy the bone marrow. Imago BioSciences has developed inhibitors of the enzyme lysine-specific demethylase 1 (LSD1). This enzyme plays a critical role in regulating the growth and development of bone marrow cells. Our first clinical inhibitor of LSD1, bomedemstat (or IMG-7289) is being studied in patients with acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms including myelofibrosis. Future clinical studies are planned for other related diseases.

keywords:N/A

N/A

Total Funding

39

Number of Employees

$5.3M

Revenue (est)

44%

Employee Growth %

$619.6M

Valuation

N/A

Accelerator

Imago BioSciences News

2022-04-17 - Brokerages Expect Imago BioSciences, Inc. (NASDAQ:IMGO) Will Announce Earnings of -$0.42 Per Share

Zero analysts have made estimates for Imago BioSciences' earnings, with the lowest EPS estimate coming in at ($0.44) and the highest estimate...

2022-04-17 - Imago BioSciences, Inc. (NASDAQ:IMGO) Expected to Post ...

On average, analysts expect that Imago BioSciences will report full year earnings of ($1.76) per share for the current fiscal year, with EPS...

2022-03-30 - Imago BioSciences Inc.

Imago BioSciences Inc is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.4M39-2%$44.7M
#2
$5.3M405%N/A
#3
$4.5M4043%N/A
#4
$4.4M40-9%N/A
#5
$35M4121%N/A

Imago BioSciences Executives


NameTitle
Wan-Jen HongChief Medical Officer
Michael ArenbergChief Operating and Business Officer
Michael ArenbergChief Operating Officer and Chief Business Officer
Hugh RienhoffCEO
Laura EichornChief Operating Officer, Interim Chief Financial Officer
Matthew PlunkettChief Financial Officer
Jennifer PeppeSenior Vice President, Clinical Operations
Amy TapperSenior Vice President, Non-Clinical and CMC
Ruth PaulVice President Regulatory Affairs